Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 5/20 | 0.42 |
| ▸ | NOS2 | P35228 | 3/20 | 0.42 |
| ▸ | NOS1 | P29475 | 2/20 | 0.42 |
| ▸ | NOS3 | P29474 | 1/20 | 0.42 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.40 |
| ▸ | ARG1 | P05089 | 1/20 | 0.39 |
| ▸ | ARG2 | P78540 | 1/20 | 0.39 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.39 |
| ▸ | GFPT1 | Q06210 | 1/20 | 0.39 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.37 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.37 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.37 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.36 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.36 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.36 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12438513 | 1.00 | KIF11 (0.42) | KIF11NOS2NOS1NOS3SLC1A1 | |
| SCHEMBL1815741 | 1.00 | KIF11 (0.42) | KIF11NOS2NOS1NOS3SLC1A1 | |
| SCHEMBL160075 | 1.00 | KIF11 (0.42) | KIF11NOS2NOS1NOS3SLC1A1 | |
| SCHEMBL12438522 | 1.00 | KIF11 (0.42) | KIF11NOS2NOS1NOS3SLC1A1 | |
| SCHEMBL12438514 | 1.00 | KIF11 (0.42) | KIF11NOS2NOS1NOS3SLC1A1 | |
| Cystine SCHEMBL25390642 | 0.98 | KIF11 (0.41) | KIF11NOS2NOS1NOS3SLC1A1 | |
| Hydrochloric Acid SCHEMBL22290069 | 0.98 | KIF11 (0.41) | KIF11NOS2NOS1NOS3SLC1A1 | |
| Hydrochloric Acid SCHEMBL3315835 | 0.98 | KIF11 (0.41) | KIF11NOS2NOS1NOS3SLC1A1 | |
| Hydrochloric Acid SCHEMBL21611699 | 0.98 | KIF11 (0.41) | KIF11NOS2NOS1NOS3SLC1A1 | |
| Hydrochloric Acid SCHEMBL21611698 | 0.98 | KIF11 (0.41) | KIF11NOS2NOS1NOS3SLC1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 159 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118580167-A | Benzenesulfonyl shikonin derivative and synthetic method and application thereof | 南京大学 | 2024-09-03 | — | — | CN | claimed |
| CN-116162255-A | Charge-convertible dendrimer and preparation method thereof | 东莞理工学院 | 2023-05-26 | — | — | CN | claimed |
| US-20220265611-A1 | ERGOTHIONEINE, S-METHYL-ERGOTHIONEINE, AND USES THEREOF | Consorcio Centro de Investigación Biomédica en Red, M.P. (ES) | 2022-08-25 | — | — | US | claimed |
| CN-114907546-A | Multifunctional polyurea acid ester derivative and preparation method and application thereof | 四川大学 | 2022-08-16 | — | — | CN | claimed |
| CN-114716635-A | Multifunctional polyurea-amino acid derivative and preparation method and application thereof | 四川大学 | 2022-07-08 | — | — | CN | claimed |
| EP-4004541-A1 | ERGOTHIONEINE, S-METHYL-ERGOTHIONEINE, AND USES THEREOF | Fundació Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) (ES) | 2022-06-01 | — | — | EP | claimed |
| WO-2021018774-A1 | ERGOTHIONEINE, S-METHYL-ERGOTHIONEINE, AND USES THEREOF | FUNDACIÓ INSTITUT D'INVESTIGACIÓ BIOMÈDICA DE BELLVITGE (IDIBELL) (ES) | 2021-02-04 | — | — | WO | claimed |
| CN-108524446-B | Functional pharmaceutical composition | 朱瑞国 | 2020-05-08 | — | — | CN | claimed |
| CN-108542882-B | Application of functional pharmaceutical composition | 陈勇 | 2020-04-17 | — | — | CN | claimed |
| CN-109651503-A | A kind of preparation method and application of artificial antigen | 天津国际生物医药联合研究院 | 2019-04-19 | — | — | CN | claimed |
| CN-103818924-A | Preparation method of titanium-silicon molecular sieve and application | CHINA TIANCHEN ENG CORP | 2014-05-28 | — | — | CN | claimed |
| CN-103675066-A | Preparation of sulfydryl graphene modified electrode and trace heavy metal detection method thereof | UNIV TIANJIN POLYTECHNIC | 2014-03-26 | — | — | CN | claimed |
| US-8450089-B2 | Compounds as L-cystine crystallization inhibitors and uses thereof | NEW YORK UNIVERSITY (US) | 2013-05-28 | — | — | US | claimed |
| EP-1874948-B1 | Process for the production of y-glutamylcysteine | NEWSOUTH INNOVATIONS PTY LTD (AU) | 2013-03-20 | — | — | EP | claimed |
| US-8236533-B2 | Process for the production of γ-glutamylcysteine | NEWSOUTH INNOVATIONS PTY LIMITED (AU) | 2012-08-07 | — | — | US | claimed |
| US-20090136993-A1 | Process for the Production of Gamma-Glutamylcysteine | NEWSOUTH INNOVATIONS PTY LIMITED | 2009-05-28 | — | — | US | claimed |
| EP-1874948-A1 | PROCESS FOR THE PRODUCTION OF y-GLUTAMYLCYSTEINE | Newsouth Innovations Pty Limited (AU) | 2008-01-09 | — | — | EP | claimed |
| WO-2006102722-A1 | PROCESS FOR THE PRODUCTION OF Ϝ-GLUTAMYLCYSTEINE | NEWSOUTH INNOVATIONS PTY LIMITED (AU) | 2006-10-05 | — | — | WO | claimed |
| EP-0222380-B1 | METHOD FOR STABILIZING CREATINE KINASE | Roche Diagnostics GmbH (DE) | 1993-03-17 | — | — | EP | claimed |
| US-4931392-A | REACTING WITH DISULFIDE OR THIOSULFONATE AND CARBOHYDRATE | BOEHRINGER MANNHEIM GMBH (DE) | 1990-06-05 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220265611-A1 | ERGOTHIONEINE, S-METHYL-ERGOTHIONEINE, AND USES THEREOF | BHMT2, GNMT, BHMT | KIF11 3842/4885NOS2 1750/4885NOS1 1773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.